Trial Profile
Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- 06 May 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Jul 2011 Planned End Date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 31 Dec 2010 New trial record